Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pheasant Study: Real-world brolucizumab effectiveness and safety in Japanese nAMD patients
jRCT1050210159Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2022
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of brolucizumab in exudative macular degeneration, sponsored by Novartis. Primary endpoint: Absence of intraretinal fluid (IRF) and subretinal fluid (SRF) at Month 12. Started Apr 2022; status: active, not recruiting.
02
Drugs
brolucizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on jRCT1050210159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1050210159.